Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Riess

Showing results (81-90 of 136) with videos related to

Pageof 14
Sort By:
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Clinical Lung Cancer|November 24, 2020
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignJonathan W Riess, Paul Frankel, David Shackelford, et al.
NPJ Precision Oncology|October 29, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatmentKevin Lu, John Paul Shen, Fernando J Lopez-Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Cancer|October 19, 2017
Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trialJohn V Hegde, Narek Shaverdian, Megan E Daly, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
British Journal of Cancer|December 3, 2013
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancerH Chen, M R Modiano, J W Neal, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2022
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancerJustin A Chen, Jasmine C Huynh, Chun-Yi Wu, et al.
JTO Clinical and Research Reports|September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA GenotypingMarissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
Cancer Research|December 13, 2018
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion ProteinsDana S Neel, David V Allegakoen, Victor Olivas, et al.
Pageof 14

Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Clinical Lung Cancer|November 24, 2020
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignJonathan W Riess, Paul Frankel, David Shackelford, et al.
NPJ Precision Oncology|October 29, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatmentKevin Lu, John Paul Shen, Fernando J Lopez-Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Cancer|October 19, 2017
Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trialJohn V Hegde, Narek Shaverdian, Megan E Daly, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
British Journal of Cancer|December 3, 2013
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancerH Chen, M R Modiano, J W Neal, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2022
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancerJustin A Chen, Jasmine C Huynh, Chun-Yi Wu, et al.
JTO Clinical and Research Reports|September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA GenotypingMarissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
Cancer Research|December 13, 2018
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion ProteinsDana S Neel, David V Allegakoen, Victor Olivas, et al.
Pageof 14